DE602004006763D1 - Verbesserte dosierform mit kontrollierter freisetzung mit stehantrieb - Google Patents

Verbesserte dosierform mit kontrollierter freisetzung mit stehantrieb

Info

Publication number
DE602004006763D1
DE602004006763D1 DE602004006763T DE602004006763T DE602004006763D1 DE 602004006763 D1 DE602004006763 D1 DE 602004006763D1 DE 602004006763 T DE602004006763 T DE 602004006763T DE 602004006763 T DE602004006763 T DE 602004006763T DE 602004006763 D1 DE602004006763 D1 DE 602004006763D1
Authority
DE
Germany
Prior art keywords
reservoir
engine
present
controlled release
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004006763T
Other languages
English (en)
Other versions
DE602004006763T2 (de
Inventor
Si-Hong Yum
Crystal Pollock-Dove
Liang-Chang Dong
Patrick S L Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of DE602004006763D1 publication Critical patent/DE602004006763D1/de
Application granted granted Critical
Publication of DE602004006763T2 publication Critical patent/DE602004006763T2/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Coating With Molten Metal (AREA)
  • Powder Metallurgy (AREA)
DE602004006763T 2003-09-26 2004-09-24 Darreichungsform zur kontrollierten Freisetzung einer Formulierung mit aktivem Mittel und Verfahren zur Herstellung der Darreichungsform Expired - Fee Related DE602004006763T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50656303P 2003-09-26 2003-09-26
US506563P 2003-09-26
PCT/US2004/031301 WO2005030164A2 (en) 2003-09-26 2004-09-24 Improved controlled release dosage form including a banded engine

Publications (2)

Publication Number Publication Date
DE602004006763D1 true DE602004006763D1 (de) 2007-07-12
DE602004006763T2 DE602004006763T2 (de) 2008-02-07

Family

ID=34393171

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004006763T Expired - Fee Related DE602004006763T2 (de) 2003-09-26 2004-09-24 Darreichungsform zur kontrollierten Freisetzung einer Formulierung mit aktivem Mittel und Verfahren zur Herstellung der Darreichungsform

Country Status (10)

Country Link
US (1) US20050186273A1 (de)
EP (1) EP1667652B1 (de)
JP (1) JP2007506753A (de)
KR (1) KR20060076318A (de)
AT (1) ATE363269T1 (de)
CA (1) CA2540044A1 (de)
DE (1) DE602004006763T2 (de)
ES (1) ES2287778T3 (de)
HK (1) HK1093430A1 (de)
WO (1) WO2005030164A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682521B2 (en) * 2000-03-23 2004-01-27 Dennis N. Petrakis Temperature activated systems
US7655001B2 (en) 2001-03-23 2010-02-02 Petrakis Dennis N Temperature responsive systems
US7607402B2 (en) 2001-03-23 2009-10-27 Petrakis Dennis N Temperature responsive systems
US7445616B2 (en) * 2001-03-23 2008-11-04 Petrakis Dennis N Temperature responsive systems
US7476224B2 (en) * 2003-03-17 2009-01-13 Petrakis Dennis N Temperature responsive systems
CA2540045A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Dosage form for controlled release of an active agent formulation
WO2007041079A2 (en) * 2005-09-30 2007-04-12 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
US20080069961A1 (en) * 2006-09-14 2008-03-20 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
CN103434229B (zh) * 2013-08-22 2015-09-16 华南理工大学 一种多层定向控释抗菌膜及其制备方法与应用
US9011964B1 (en) * 2014-12-06 2015-04-21 Albert S. Zeng Nano-encapsulated, controlled drug manufacturing process
EP3487485A2 (de) 2016-07-19 2019-05-29 Johnson & Johnson Consumer Inc. Tabletten mit unterbrochenen beschichteten regionen
US10583089B2 (en) 2016-07-19 2020-03-10 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions
US20220395273A1 (en) * 2021-06-10 2022-12-15 Cilag Gmbh International Systems, devices and methods of repairing tendons and ligaments

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4478658A (en) * 1982-12-20 1984-10-23 Warner-Lambert Company Method for sealing non-enteric capsules
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5245357A (en) * 1988-09-07 1993-09-14 Seiko Epson Corporation Page printer
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6153678A (en) * 1997-10-06 2000-11-28 Alza Corporation Injection-moldable composition and article of manufacture comprising same
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365183B1 (en) * 1998-05-07 2002-04-02 Alza Corporation Method of fabricating a banded prolonged release active agent dosage form
US6183466B1 (en) * 1998-08-21 2001-02-06 Alza Corporation Dosage form comprising a capsule
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
ATE292453T1 (de) * 1999-12-09 2005-04-15 Alza Corp Antivirale arznei
DE10036173A1 (de) * 2000-07-25 2002-02-07 Basf Ag Verfahren zum Entsäuern eines Fluidstroms und Waschflüssigkeit zur Verwendung in einem derartigen Verfahren
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
HUP0402451A3 (en) * 2001-12-19 2008-04-28 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
IL162294A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
HK1093430A1 (en) 2007-03-02
WO2005030164A3 (en) 2006-03-30
EP1667652A2 (de) 2006-06-14
WO2005030164A2 (en) 2005-04-07
CA2540044A1 (en) 2005-04-07
JP2007506753A (ja) 2007-03-22
US20050186273A1 (en) 2005-08-25
ES2287778T3 (es) 2007-12-16
EP1667652B1 (de) 2007-05-30
KR20060076318A (ko) 2006-07-04
DE602004006763T2 (de) 2008-02-07
ATE363269T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
HK1093430A1 (en) Improved controlled release dosage form including a banded engine
CL2004000927A1 (es) Forma de dosificacion transdermica que comprende un agente activo, una superficie proxima y una superficie distal.
BRPI0509127A (pt) agentes terapêuticos para distúrbios do ouvido interno contendo um antagonista de il-6 como ingredientes ativo
WO2007034188A3 (en) Chemo-immunotherapy method
TW200600111A (en) Improved dental whitening method
MX2007000564A (es) Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.
WO2007103510A3 (en) Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
SE0301882D0 (sv) New use I
SE0301886D0 (sv) New use V
WO2004064769A3 (en) Methods for making and using topical delivery agents
WO2006071613A3 (en) Injectable non-aqueous suspension
DE60111500D1 (de) Neue wirkstoffkombination, enthaltend einen inhibitor der epinephrinaufnahme sowie einen antimuskarinen wirkstoff
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2003002056A3 (en) Composition with enhance cetylpyridinium chloride activity and method of using the same
WO2006023814A3 (en) Effervescent composition including a grape-derived component
WO2005084377A3 (en) Combination therapy with glatiramer acetate and riluzole
BR0317924A (pt) Formas de dosagem não aquosas de composto de prostaglandina e
MX2007005121A (es) Composicion que comprende acetaminofen, cafeina y opcionalmente aspirina junto con un agente alcalino para mejorar la absorcion.
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
WO2001041754A8 (en) Inhibitors of collagen-induced platelet aggregation
WO2006124753A3 (en) Antipyretic agents against vr1-antagonist-induced increases in body temperature
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
WO2002007731A3 (en) Composition containing a 15-keto prostaglandin compound for treating of ocular hypertension and glaucoma
BR0015980A (pt) Agente para profilaxia ou tratamento do glaucoma, e, uso de um antagonista de angiotensina ii
WO2005020919A3 (en) Method of treatment and bioassay involving macrophage migration inhibitory factor (mif) as cardiac-derived myocardial depressant factor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee